AGR3 in Breast Cancer: Prognostic Impact and Suitable Serum-Based Biomarker for Early Cancer Detection

@article{Garczyk2015AGR3IB,
  title={AGR3 in Breast Cancer: Prognostic Impact and Suitable Serum-Based Biomarker for Early Cancer Detection},
  author={Stefan Garczyk and Saskia von Stillfried and Wiebke Antonopoulos and Arndt Hartmann and Michael G. Schrauder and Peter Andreas Fasching and Tobias Anzeneder and Andrea Tannapfel and Y. Erg{\"o}nenc and Ruth Kn{\"u}chel and Michael Rose and Edgar Dahl},
  journal={PLoS ONE},
  year={2015},
  volume={10}
}
Blood-based early detection of breast cancer has recently gained novel momentum, as liquid biopsy diagnostics is a fast emerging field. In this study, we aimed to identify secreted proteins which are up-regulated both in tumour tissue and serum samples of breast cancer patients compared to normal tissue and sera. Based on two independent tissue cohorts (n = 75 and n = 229) and one serum cohort (n = 80) of human breast cancer and healthy serum samples, we characterised AGR3 as a novel potential… Expand
Identification and prognostic value of anterior gradient protein 2 expression in breast cancer based on tissue microarray
TLDR
Anterior gradient protein 2 expression was significantly associated with histologic type, histological grade, oestrogen status and progesterone status, and univariate analysis of clinicopathological variables showed that anterior gradientprotein 2 expression, tumour size and lymph node status were significantly correlated with overall survival in patients with grade 1 and 2 tumours. Expand
AGR2 and AGR3 play an important role in the clinical characterization and prognosis of basal like breast cancer.
TLDR
AGR2 and AGR3 expression were able to differentiate non-BLBC from BLBC and both genes behave different when considering prognosis and molecular stratification. Expand
Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer
TLDR
This review summarizes and focuses on the recent discoveries of promising macromolecules and cell-based biomarkers for the diagnosis and prognosis of breast cancer and provide implications for therapeutic strategies. Expand
The Utility of SOX2 and AGR2 Biomarkers as Early Predictors of Tamoxifen Resistance in ER-Positive Breast Cancer Patients
TLDR
Integrated use of SOX2 and AGR2 biomarkers with serum A GR2 assay holds a promising hope for their future use as predictive markers for early detection of tamoxifen resistance in ER-positive breast cancer patients. Expand
Identification of non-invasive biomarkers for early detection of breast cancer: A Review
TLDR
It is revealed that using any individual biomolecule as a biomarker is not sufficient to diagnose breast cancer at early stages rather it is suggested that a panel of proteins or miRNAs would offer better sensitivity and specificity. Expand
High‐throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype‐specific serologically relevant biomarkers
TLDR
The results of this analysis strongly support the data, with eight of the proteins potentially representing biomarkers for stratification of BC subtypes being found to stratify the tumor subtype‐specific TIFs. Expand
The future of blood-based biomarkers for the early detection of breast cancer.
TLDR
The latest discoveries for harnessing blood-based biomarkers as novel BC screening tools are summarized, as well as the limitations and challenges that need to be overcome before the translation of their use from the bench to the bedside are discussed. Expand
Screening and identification of potential biomarkers in triple-negative breast cancer by integrated analysis.
TLDR
The gene function enrichment in TNBC was revealed, such as basal cell carcinoma, prostate cancer, oocyte meiosis and choline metabolism in cancer pathways, and the PPI network reconstruction would benefit the screening of hubs. Expand
Profile of anterior gradient 3 (AGR3) mRNA expression and serum levels in benign and malignant breast tumors.
TLDR
AGR3 mRNA expression and serum protein levels in patients with benign and malignant breast tumors are profiles and AGR3 is associated with non-aggressive tumors and could be used as a marker for less aggressive breast tumors. Expand
Anterior Gradient 3 Promotes Breast Cancer Development and Chemotherapy Response
  • Q. Xu, Ying Shao, +7 authors Yongjie Ma
  • Medicine
  • Cancer research and treatment : official journal of Korean Cancer Association
  • 2019
TLDR
Investigating if AGR3 had prognostic values in invasive ductal carcinoma (IDC) of breast cancer and could promote tumor progression found it to be a potential prognostic indicator in luminal B subtype of IDC patients of histological grade I-II. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 67 REFERENCES
Prognostic Relevance of AGR2 Expression in Breast Cancer
TLDR
The expression of A GR2 in breast cancer is strongly associated with markers of tumor differentiation (estrogen receptor positivity, lower tumor grade) and prognostic effect of AGR2 for overall survival could be shown, which became independently significant for the group of nodal-negative tumors. Expand
Supervised risk predictor of breast cancer based on intrinsic subtypes.
TLDR
D diagnosis by intrinsic subtype adds significant prognostic and predictive information to standard parameters for patients with breast cancer. Expand
Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening
TLDR
Tumor-specific methylation of the three-gene panel (ITIH5, DKK3, and RASSF1A) might be a valuable biomarker for the early detection of breast cancer. Expand
Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9
TLDR
Additional serum biomarkers, particularly SYCN and REG1B, when combined with CA19.9, show promise as improved diagnostic indicators of pancreatic cancer, which therefore warrants further validation. Expand
AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration
TLDR
Human anterior gradient 2 (AGR2) is a potential biomarker for the diagnosis of mucinous ovarian cancer and an ELISA assay may facilitate the early detection of mucineous ovarian cancer using patient serum. Expand
Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients
TLDR
A rabbit antibody to recombinant human AGR2 was used to assess its prognostic significance in a retrospective cohort of 351 breast cancer patients treated by adjuvant hormonal therapy, finding a significant association with patient death over a 10-year period. Expand
Development of serum parameters panels for the early detection of pancreatic cancer
TLDR
The authors' parameter panels may aid in the early detection of PDAC to improve clinical outcome and identify cancer selectivity in healthy controls and patients with benign pancreatitis. Expand
Serum AGR2 as an early diagnostic and postoperative prognostic biomarker of human lung adenocarcinoma.
TLDR
Positive serum AGR2 expression was significantly associated with the incidence of recurrence after surgery and with a poor prognosis and might become a clinically useful biomarker for early detection, prediction ofRecurrence and prognosis with lung adenocarcinomas. Expand
Expression of the glioma-associated oncogene homolog (GLI) 1 in human breast cancer is associated with unfavourable overall survival
TLDR
Elevated levels of GLI1 protein in human breast cancer are associated with unfavourable prognosis and progressive stages of disease and this study indicates that altered hedgehog signalling may represent a key disease pathway in the progression of human breast cancers. Expand
Expression of AGR2 in non small cell lung cancer.
TLDR
Interestingly, this is the first study to demonstrate AGR2 expression in squamous cell carcinomas, and a prognostic value of Agr2 could not be demonstrated neither in multivariate nor in univariate analyses. Expand
...
1
2
3
4
5
...